Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 4Active not recruiting 4Terminated 2Completed 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 126Leukemia, Lymphocytic, Chronic, B-Cell 30Myelodysplastic Syndromes 27Leukemia 22Recurrence 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 10Leukemia, Biphenotypic, Acute 8Hematologic Neoplasms 8Burkitt Lymphoma 8Leukemia, Myelomonocytic, Chronic 7Neoplasm, Residual 6Multiple Myeloma 6Lymphoma, Mantle-Cell 6Waldenstrom Macroglobulinemia 5Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell, Marginal Zone 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Myeloproliferative Disorders 4Leukemia, Myeloid 4Lymphoma, Large B-Cell, Diffuse 3Leukemia, Monocytic, Acute 3GATA2 Deficiency 3Sarcoma, Myeloid 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Immunoglobulin Light-chain Amyloidosis 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Specimen Handling 9fludarabine 8Cyclophosphamide 7Biopsy 6ruxolitinib 5Whole-Body Irradiation 5Stem Cell Transplantation 5Azacitidine 5venetoclax 4Tacrolimus 4Injections 4Cytarabine 4Busulfan 4ivosidenib 3fludarabine phosphate 3Thiotepa 3Mycophenolic Acid 3Melphalan 3Cyclosporins 3CPX-351 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3luspatercept 2decitabine and cedazuridine drug combination 2X-Rays 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Liposomes 2Gemtuzumab 2Daunorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Myeloproliferative Disorders × venetoclax × Clear all
NCT05554406 2026-05-27

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
335 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-05-26

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03471260 2026-03-11

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
96 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05074355 2025-12-18

Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

University Health Network, Toronto

Phase 2 Recruiting
40 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡